ImmunityBio’s cell therapy posts encouraging early data in rare blood cancernews2026-01-16T16:05:02+00:00January 16th, 2026|Endpoints News|
Ocugen touts Phase 2 data for eye disease gene therapynews2026-01-15T13:15:39+00:00January 15th, 2026|Endpoints News|
J&J reports positive Phase 3 data for Tecvayli in earlier blood cancer settingnews2026-01-15T11:52:54+00:00January 15th, 2026|Endpoints News|
Novo Nordisk Foundation to inject $850M+ into BioInnovation Institute through 2035news2026-01-15T08:30:28+00:00January 15th, 2026|Endpoints News|
Scribe Therapeutics plans to test cholesterol-lowering therapy this summernews2026-01-14T21:11:18+00:00January 14th, 2026|Endpoints News|
Jazz sells priority review voucher for $200M, scoring highest price in a decadenews2026-01-14T18:44:04+00:00January 14th, 2026|Endpoints News|
Marea takes drug for acromegaly to Phase 2news2026-01-13T13:00:12+00:00January 13th, 2026|Endpoints News|
#JPM26: Moderna CEO Bancel talks deals, flu and RSV strategynews2026-01-12T12:00:35+00:00January 12th, 2026|Endpoints News|
Novartis, SciNeuro to work together on preclinical amyloid-targeting drug for Alzheimer’snews2026-01-12T11:56:20+00:00January 12th, 2026|Endpoints News|
Mirador raises $250M, with plans to become an immunology powerhousenews2026-01-11T13:30:31+00:00January 11th, 2026|Endpoints News|
